AUSTIN, Texas — (BUSINESS WIRE) — Apollo Endosurgery, Inc. (Nasdaq: APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the closing of its previously announced underwritten public offering of 4,309,090 shares of its common stock, including 562,055 shares sold pursuant to the underwriter’s exercise in full of its option to purchase additional shares to cover over-allotments. Gross proceeds from the offering at a public offering price of $5.50 per share, before underwriting discounts and commissions and offering expenses, were approximately $23.7 million. All of the common stock was offered and sold by Apollo.
Craig-Hallum Capital Group acted as the sole managing underwriter for the offering.
A shelf registration statement on Form S-3 relating to the offered shares of common stock was filed with the Securities and Exchange Commission (the “SEC”), and was declared effective on December 20, 2017. A prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related to the offering may be obtained from Craig-Hallum Capital Group LLC at 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets, by telephone at 612-334-6300, or by e-mail at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies for the treatment of obesity, a condition facing over 650 million people globally, as well as other gastrointestinal conditions. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the ORBERA® Intragastric Balloon, and the LAP-BAND® Adjustable Gastric Banding System.
Apollo’s common stock is traded on the Nasdaq Global Market under the symbol “APEN.”
Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
Chief Financial Officer